Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis.
暂无分享,去创建一个
Mitchell D Schnall | Robert D Cardiff | Katherine D Dugan | R. Cardiff | L. Chodosh | M. Schnall | S. Moody | C. J. Sarkisian | S. Pickup | E. Gunther | Lewis A Chodosh | K. Hahn | Edward J Gunther | Susan E Moody | Kristina T Hahn | Nathalie Innocent | Christopher J Sarkisian | Steven Pickup | Nathalie Innocent | Katherine D. Dugan | Kristina T. Hahn
[1] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[2] R. Cardiff,et al. The Comparative Pathology of Human and Mouse Mammary Glands , 2004, Journal of Mammary Gland Biology and Neoplasia.
[3] Lyndsay N Harris,et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] G. Hortobagyi,et al. Targeting HER2: recent developments and future directions for breast cancer patients. , 2001, Seminars in oncology.
[5] M. Hung,et al. HER2 overexpression and cancer targeting. , 2001, Seminars in oncology.
[6] Kenneth Chu,et al. Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC , 2002, Science.
[7] B. Groner,et al. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. , 1988, Cancer research.
[8] G. Hortobagyi. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. , 2001, Seminars in oncology.
[9] L. Chin,et al. Essential role for oncogenic Ras in tumour maintenance , 1999, Nature.
[10] H. Varmus,et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. , 2001, Genes & development.
[11] L. Chodosh,et al. Brca2 is coordinately regulated with Brca1 during proliferation and differentiation in mammary epithelial cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[12] R. Cardiff,et al. Mammary Disease Mice Model Premalignant Polyoma Middle-T Transgenic Updated Version , 2001 .
[13] D. Tenen,et al. Reversibility of acute B-cell leukaemia induced by BCR–ABL1 , 2000, Nature Genetics.
[14] R. Cardiff,et al. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[15] R. Cardiff,et al. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations , 2001, Nature Medicine.
[16] D. Felsher,et al. Reversible tumorigenesis by MYC in hematopoietic lineages. , 1999, Molecular cell.
[17] R. Cardiff,et al. The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting‡ , 2000, Oncogene.
[18] P. Leder,et al. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene , 1988, Cell.
[19] P. Jolicoeur,et al. Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene , 1989, Cell.
[20] Robert B Boxer,et al. A novel doxycycline‐inducible system for the transgenic analysis of mammary gland biology , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[21] N. Robert,et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] G. Evan,et al. Suppression of Myc-Induced Apoptosis in β Cells Exposes Multiple Oncogenic Properties of Myc and Triggers Carcinogenic Progression , 2002, Cell.
[23] D Tripathy,et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Cori Bargmann,et al. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185 , 1986, Cell.
[25] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[26] R. Cardiff,et al. Transgenic mouse models of mammary tumorigenesis. , 1993, Cancer surveys.